Related Experiment Video
Updated: Apr 18, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA
Biao Yan1, Jin Yao2, Jing-Yu Liu2
1From the Department of Central Laboratory, Eye Hospital (B.Y., J.-Y.L., J.Y., X.-M.L., X.-Q.W., Y.-J.L., Z.-F.T., Y.-C.S., Q.J.), Department of Ophthalmology, The Fourth School of Clinical Medicine (B.Y., J.Y., Q.J.), and Department of Pathophysiology, School of Basic Medical Sciences (Q.C.), Nanjing Medical University, Nanjing, China. yanbiao1982@hotmail.com jqin710@vip.sina.com.cn.
Rationale:
Pathological angiogenesis is a critical component of diseases, such as ocular disorders, cancers, and atherosclerosis. It is usually caused by the abnormal activity of biological processes, such as cell proliferation, cell motility, immune, or inflammation response. Long noncoding RNAs (lncRNAs) have emerged as critical regulators of these biological processes. However, the role of lncRNA in diabetes mellitus-induced microvascular dysfunction is largely unknown.
Objective:
To elucidate whether lncRNA-myocardial infarction-associated transcript (MIAT) is involved in diabetes mellitus-induced microvascular dysfunction.
Methods And Results:
Using quantitative polymerase chain reaction, we demonstrated increased expression of lncRNA-MIAT in diabetic retinas and endothelial cells cultured in high glucose medium. Visual electrophysiology examination, TUNEL staining, retinal trypsin digestion, vascular permeability assay, and in vitro studies revealed that MIAT knockdown obviously ameliorated diabetes mellitus-induced retinal microvascular dysfunction in vivo, and inhibited endothelial cell proliferation, migration, and tube formation in vitro. Bioinformatics analysis, luciferase assay, RNA immunoprecipitation, and in vitro studies revealed that MIAT functioned as a competing endogenous RNA, and formed a feedback loop with vascular endothelial growth factor and miR-150-5p to regulate endothelial cell function.
Conclusions:
This study highlights the involvement of lncRNA-MIAT in pathological angiogenesis and facilitates the development of lncRNA-directed diagnostics and therapeutics against neovascular diseases.
Insights
Long noncoding RNA MIAT is implicated in diabetes-induced microvascular dysfunction. Targeting MIAT may offer new therapeutic strategies for neovascular diseases by regulating pathological angiogenesis.
Area of Science:
- Molecular Biology
- Genetics
- Ophthalmology
Background:
- Pathological angiogenesis drives diseases like cancer and ocular disorders.
- Long noncoding RNAs (lncRNAs) regulate key biological processes involved in angiogenesis.
- The role of lncRNAs in diabetes mellitus-induced microvascular dysfunction remains unclear.
Purpose of the Study:
- To investigate the involvement of lncRNA-MIAT in diabetes mellitus-induced microvascular dysfunction.
- To understand the regulatory mechanism of MIAT in diabetic retinopathy.
Main Methods:
- Quantitative polymerase chain reaction (qPCR) to measure MIAT expression.
- In vivo studies using diabetic mouse models and in vitro endothelial cell assays.
- Bioinformatics analysis, luciferase assays, and RNA immunoprecipitation to elucidate molecular interactions.
Main Results:
- Increased expression of lncRNA-MIAT was observed in diabetic retinas and high glucose-treated endothelial cells.
- MIAT knockdown ameliorated diabetic microvascular dysfunction and inhibited endothelial cell proliferation, migration, and tube formation.
- MIAT acts as a competing endogenous RNA, forming a feedback loop with VEGF and miR-150-5p.
Conclusions:
- lncRNA-MIAT plays a significant role in pathological angiogenesis in diabetes.
- MIAT is a potential diagnostic and therapeutic target for neovascular diseases.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
